A5031448289- Phagocytosis and Immune Regulation
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Pancreatic and Hepatic Oncology Research
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Immunotherapy and Immune Responses
- Single-cell and spatial transcriptomics
- Chemokine receptors and signaling
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Immune cells in cancer
- Cancer Cells and Metastasis
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Gastrointestinal Tumor Research and Treatment
- Cancer Genomics and Diagnostics
Heidelberg University
2021-2025
German Cancer Research Center
2021-2024
University Medical Centre Mannheim
2023-2024
University Hospital Heidelberg
2021-2024
DKFZ-ZMBH Alliance
2021-2024
German Center for Lung Research
2023
Cancer Institute (WIA)
2022
University Medical Center
2022
Circulating tumor cells (CTCs) hold immense promise for unraveling heterogeneity and understanding treatment resistance. However, conventional methods, especially in cancers like non-small cell lung cancer (NSCLC), often yield low CTC numbers, hindering comprehensive analyses. This study addresses this limitation by employing diagnostic leukapheresis (DLA) to patients, enabling the screening of larger blood volumes. To leverage DLA's full potential, introduces a novel approach enrichment from DLAs.
Abstract Beyond first line, the prognosis of relapsed/refractory (R/R) acute myeloid leukemia (AML) patients is poor with limited treatment options. Bemcentinib an orally bioavailable, potent, highly selective inhibitor AXL, a receptor tyrosine kinase associated prognosis, chemotherapy resistance and decreased antitumor immune response. We report bemcentinib monotherapy bemcentinib+low-dose cytarabine combination therapy arms from completed BerGenBio-funded open-label Phase 1/2b trial...
Tissue adaptation is required for regulatory T (Treg) cell function within organs. Whether this program shares aspects with other tissue-localized immune populations unclear. Here, we analyzed single-cell chromatin accessibility data, including the transposable element (TE) landscape of CD45
Regulatory T (Treg) cells, a subset of CD4+ play crucial role in immunoregulation. Notably, CCR8-expressing Treg cells tissues also contribute to organ homeostasis and repair. To determine whether these tissue-regenerative programs are active the tumor microenvironment, we employed single-cell chromatin accessibility genome-wide DNA methylation analyses investigate CCR8+ tissue isolated from human adjacent tumor-free tissues. Our findings indicate that corresponding exhibit high degree...
The prognosis of pancreatic cancer has improved only modestly in recent years. This is partly due to the lack development precision oncology including immune this entity. Rearrangements proto-oncogene tyrosine protein kinase ROS1 gene represent driver alterations found especially lung cancer. Tyrosine inhibitors (TKI) with activity against lorlatinib substantially outcome patient population. Anecdotal evidence reports treatment harboring fusions TKI, but data concerning patients point...
Abstract The long-term consequences of cancer or therapy on the patients’ immune system years after cancer-free survival remain poorly understood. Here, we have performed an in-depth characterization bone marrow ecosystem multiple myeloma survivors at initial diagnosis and up to 17 following survival. Using comparative single-cell analyses in combination with molecular, genomic functional approaches, demonstrate that display pronounced alterations their microenvironment associated impaired...
BCR-ABL negative myeloproliferative neoplasms (MPNs) consist of essential thrombocythemia, polycythemia vera, and myelofibrosis. The majority patients harbor the JAK2 -activating mutation V617F. inhibitors were shown to reduce symptom burden splenomegaly in MPN patients. However, treatment options are limited after failure inhibitors. AXL, a member TAM family receptor tyrosine kinases, mediates survival therapy resistance different myeloid cancers including acute leukemia chronic leukemia....
Abstract The long-term consequences of cancer and its therapy on the patients’ immune system years after cancer-free survival remain poorly understood. Here, we present an in-depth characterization bone marrow ecosystem multiple myeloma survivors, from initial diagnosis up to 17 following a single line survival. Using comparative single-cell analyses combined with molecular, genomic, functional approaches, demonstrate that survivors exhibit pronounced alterations in their microenvironment...
Background: The new standard of care (SOC) in newly-diagnosed AML patients (pts) unfit for intensive chemotherapy (IC) due to age or co-morbidities yields favourable efficacy. However, beyond 1st line, these pts have limited treatment options, with a dismal mOS 2.4 months at relapse, highlighting significant unmet need treatments this pt population. Bemcentinib (BEM) is first-in-class, orally bioavailable, highly selective AXL-inhibitor. AXL (a receptor tyrosine kinase) represents an...
The Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) is a cutting-edge technology that enables researchers to assess genome-wide chromatin accessibility and characterize cell type specific gene-regulatory programs. Recent technological progress allows this also on the single-cell level. In article, we describe whole value chain from isolation of T cells murine tissues complete bioinformatic analysis workflow. We start with methods isolating scATAC-seq-ready CD4+ such as...